Yi Yang, Bo Chen, Chongming Zheng, Hao Zeng, Junxi Zhou, Yaqing Chen, Qing Su, Jingxian Wang, Juejin Wang, Yurong Wang, Hongli Wang, Ruxue Jin, Zhiyuan Bo, Gang Chen, Yi Wang
BACKGROUND & AIMS: Glucose-lowering drug is associated with various cancers, but the causality with gastrointestinal cancer risk is rarely reported. We aimed to explore the causality between them in this Mendelian randomization (MR) study. METHODS: Two-sample MR, summary-data-based (SMR), mediation MR, and colocalization analyses was employed. Ten glucose-lowering drug targets (PPARG, DPP4, GLP1R, INSR, SLC5A2, ABCC8, KCNJ11, ETFDH, GPD2, PRKAB1) and seven types of gastrointestinal cancer (anal carcinoma, cardia cancer, gastric cancer, hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), pancreatic cancer, rectum cancer) were included...
March 19, 2024: Cell & Bioscience